We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Cardiomyopathy Tissue Bank in a Cancer Population

This study is currently recruiting participants.
Verified August 2017 by M.D. Anderson Cancer Center
Sponsor:
ClinicalTrials.gov Identifier:
NCT00500734
First Posted: July 13, 2007
Last Update Posted: August 8, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
Information provided by (Responsible Party):
M.D. Anderson Cancer Center
  Purpose
The goal of this laboratory research study is to collect and store blood and tissue from patients who have a diagnosis of heart disease and may be at a high risk for the development of heart failure. This blood may be used in the future to identify genes that may play a role in developing congestive heart failure (CHF) from chemotherapy or other sources.

Condition Intervention
Heart Disease Procedure: Blood Sample

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Prospective
Official Title: Cardiomyopathy Tissue Bank in a Cancer Population

Resource links provided by NLM:


Further study details as provided by M.D. Anderson Cancer Center:

Primary Outcome Measures:
  • Baseline Patient Demographic Information (age, sex, race) [ Time Frame: One time visit. ]
  • Identification biological markers predisposing cancer patients to development of chemotherapy-induced congestive heart failure [ Time Frame: One time visit for collection of blood and tissue samples. ]

Biospecimen Retention:   Samples With DNA
Blood and tissue collection. This blood may be studied in the future to try to find possible genetic or biochemical markers that may be the cause of CHF.

Estimated Enrollment: 1000
Actual Study Start Date: December 4, 2002
Estimated Study Completion Date: December 2018
Estimated Primary Completion Date: December 2018 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
Heart Disease Patients Procedure: Blood Sample
One time blood draw of 2 teaspoons.

Detailed Description:

You will have a one time blood draw of 2 teaspoons of blood for use in future research. This blood may be studied in the future to try to find possible genetic or biochemical markers that may be the cause of CHF. Your blood will be drawn either on an outpatient basis or during a routine visit to the hospital. If you already have a central line or an IV placed, the blood will be drawn at these sites to decrease the pain and discomfort of the blood draw. The information obtained in this study will not be put into your medical records.

This is an investigational study. All will be enrolled at MD Anderson.

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   2 Months and older   (Child, Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients diagnosed with heart disease and that may be at a high risk for the development of heart failure.
Criteria

Inclusion Criteria:

  • Patients who are at high risk for developing Cardiomyopathy or Congestive Heart Failure.
  • Patients two months of age and older.

Exclusion Criteria:

  • Those that are not willing to sign an informed consent.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00500734


Contacts
Contact: Jean-Bernard Durand, MD 713-792-6239

Locations
United States, Texas
University of Texas MD Anderson Cancer Center Recruiting
Houston, Texas, United States, 77030
Principal Investigator: Jean-Bernard Durand, MD         
Sponsors and Collaborators
M.D. Anderson Cancer Center
Investigators
Principal Investigator: Jean-Bernard Durand, MD M.D. Anderson Cancer Center
  More Information

Additional Information:
Responsible Party: M.D. Anderson Cancer Center
ClinicalTrials.gov Identifier: NCT00500734     History of Changes
Other Study ID Numbers: ID02-359
First Submitted: July 12, 2007
First Posted: July 13, 2007
Last Update Posted: August 8, 2017
Last Verified: August 2017

Keywords provided by M.D. Anderson Cancer Center:
Cardiomyopathy
Tissue Bank
Heart Disease
Heart Failure
Congestive Heart Failure

Additional relevant MeSH terms:
Heart Diseases
Cardiomyopathies
Cardiovascular Diseases